Abound Wealth Management’s Arcus Biosciences RCUS Stock Holding History

Abound Wealth Management’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$155	Hold	5	–	–	﹤0.01%	1178
2026 Q1	$108	Buy	+5	New	+$108	﹤0.01%	1397
2024 Q3	–	Sell	-13	Closed	-$198	–	1333
2024 Q2	$198	Hold	13	–	–	﹤0.01%	1106
2024 Q1	$246	Sell	13 -9	-41%	-$156	﹤0.01%	1204
2023 Q4	$421	Buy	+22	New	+$352	﹤0.01%	999

Other funds holding RCUS

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

SAM

Seelaus Asset Management Chatham, New Jersey $142M AUM 48.54% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

HPC

HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Abound Wealth Management's RCUS Position: Q2 2026 in Review

Abound Wealth Management held its Arcus Biosciences (RCUS) position steady in Q2 2026 at 5 shares worth $155. The position accounts for ﹤0.01% of the portfolio, ranked #1178.

Abound Wealth Management first reported a position in RCUS in Q4 2023 and has held it in 5 quarters since. The position peaked at $421 in Q4 2023. 17 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

Abound Wealth Management held 5 shares of Arcus Biosciences worth $155 as of Q2 2026.
Abound Wealth Management left its Arcus Biosciences share count unchanged in Q2 2026.
Arcus Biosciences made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #1178 holding.
Abound Wealth Management first reported a position in Arcus Biosciences in Q4 2023 and has held it in 5 quarters since.
Abound Wealth Management's Arcus Biosciences position peaked at $421 in Q4 2023.
17 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.